This study applied bioinformatics and systematic pharmacology to investigate the molecular mechanism of mylabris in the treatment of leukemia.Based on the bioinformatics identification of common targets of mylabris and leukemia-related genes, we show that the effective components of mylabris act simultaneously on two key gene targets, PTEN and TP53, as well as the p53 signaling pathway, to inhibit the proliferation of leukemic cells. The gene discussed is TP53; the disease is leukemia.